CeriBell (NASDAQ:CBLL - Get Free Report) shares gapped up prior to trading on Friday . The stock had previously closed at $11.15, but opened at $12.98. CeriBell shares last traded at $14.56, with a volume of 593,673 shares changing hands.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently issued reports on the company. Canaccord Genuity Group reissued a "buy" rating and set a $33.00 target price on shares of CeriBell in a research note on Wednesday, February 26th. LADENBURG THALM/SH SH assumed coverage on CeriBell in a report on Friday, April 4th. They issued a "buy" rating and a $32.00 target price for the company. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $32.50.
Read Our Latest Research Report on CeriBell
CeriBell Price Performance
The stock's fifty day moving average price is $20.88.
CeriBell (NASDAQ:CBLL - Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.08). The firm had revenue of $18.53 million during the quarter, compared to the consensus estimate of $17.55 million. As a group, sell-side analysts anticipate that CeriBell will post -2.46 EPS for the current fiscal year.
Institutional Investors Weigh In On CeriBell
Large investors have recently modified their holdings of the stock. FMR LLC purchased a new position in shares of CeriBell in the fourth quarter worth approximately $128,120,000. TPG GP A LLC acquired a new stake in shares of CeriBell in the fourth quarter worth $102,677,000. Red Tree Management LLC purchased a new stake in CeriBell in the 4th quarter worth about $57,083,000. Yu Fan purchased a new position in CeriBell during the 4th quarter valued at about $31,631,000. Finally, ABG WTT Global Life Science Capital Partners GP Ltd purchased a new stake in shares of CeriBell in the fourth quarter worth approximately $28,160,000.
CeriBell Company Profile
(
Get Free Report)
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Further Reading
Before you consider CeriBell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CeriBell wasn't on the list.
While CeriBell currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
